Gilead Sciences (GILD) cash: $7.6B
Gilead Sciences held $7.6B in cash and cash equivalents on Dec 31, 2025, down 24.3% from $10B a year earlier.
From Gilead Sciences's filings with the SEC · Read the filing · GILD stock page
Gilead Sciences cash by year
#83 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $7.6B | -24% |
| Dec 31, 2024 | $10B | +64% |
| Dec 31, 2023 | $6.1B | +12% |
| Dec 31, 2022 | $5.4B | +1% |
| Dec 31, 2021 | $5.3B | – |
Cash of similar companies
Companies in the same industry as Gilead Sciences, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Amgen | $9.1B | Dec 31, 2025 |
| Gilead Sciences | $7.6B | Dec 31, 2025 |
| Biogen | $3B | Dec 31, 2025 |
| Moderna | $2.6B | Dec 31, 2025 |
| Immunovant | $995M | Dec 31, 2025 |
| Qiagen | $839M | Dec 31, 2025 |
| Recursion Pharmaceuticals | $743M | Dec 31, 2025 |
Questions and answers
What is Gilead Sciences's cash?
Gilead Sciences held $7.6B in cash and cash equivalents on Dec 31, 2025, down 24.3% from $10B a year earlier.
Numbers as reported in Gilead Sciences's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology